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Abstract: Breast cancer is a leading cause of cancer-related deaths worldwide, predominantly
caused by metastasis. It is generally accepted that the pattern of breast cancer metastasis is largely
determined by the interaction between the chemokine receptors on cancer cells and the chemokines
expressed at the sites of metastatic disease. Chemokine receptors belong to the G-protein-coupled
receptors (GPCRs) family that appear to be implicated in inflammatory diseases, tumor growth
and metastasis. One of its members, C-C Chemokine receptor 7 (CCR7), binds chemokines CCL19
and CCL21, which are important for tissue homeostasis, immune surveillance and tumorigenesis.
These receptors have been shown to induce the pathobiology of breast cancer due to their ability to
induce cellular proliferation and migration upon the binding of the cognate chemokine receptors.
The underlying signaling pathways and exact cellular interactions within this biological system are
not fully understood and need further insights. Thus, in this review, we summarize the essential roles
of CCR7 and its receptors in breast cancer progression. Furthermore, we discuss the mechanisms of
regulation that may lead to novel opportunities for therapeutic intervention. Despite the enormous
advances in our knowledge of the nature of the chemokines in breast cancer metastasis, research
about the involvement of CCR7 in cancer progression is still limited. Therefore, further studies are
essential to illustrate the distinct roles of CCR7 in cancer progression and validate its potential as a
preventive bio-factor for human breast cancer metastasis by targeting chemokine receptor genes.
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1. Introduction
Since their discovery over 30 years ago, numerous chemokines have been identified, with new
roles emerging past the homing of leukocytes [1]. Chemokines or chemotactic cytokines constitute a
large family of small (8–12 kDa) structurally related polypeptides that exert their functions by binding
specific Gαi-protein-coupled chemokine receptors (GPCR) on the cell surface to induce chemotaxis [2].
Structurally, to date, more than 40 human chemokines have been described. The most widely used
nomenclature subdivides chemokines into four subfamilies (CC, CXC, CX3C and XC) according to the
position of the first two N-terminal cysteine residues in their amino acid sequence where C represents
the cysteine and X is any amino acid [1].
Currently, 22 chemokine receptors have been identified in humans. These are G-protein-coupled
receptors (GPCRs)-integral seven-transmembrane glycoproteins domains (connected by three
intracellular and three extracellular loops), a short extracellular N-terminal that will bind to the
ligand and an intracellular C-terminal coupled to the group of G-protein receptors. In the literature,
four “atypical” receptors have been described capable of binding chemokines with high affinity
with no signaling or signaling which is not mediated by G-proteins. This group of receptors has
also been named “scavenger” receptors and recently renamed to “ACKR”, the acronym of atypical
chemokine receptor [3]. Receptor–ligand interaction leads to signal transduction involving G-proteins
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which promotes the release of intracellular second messengers such as calcium, cyclic adenosine
monophosphate (cAMP) and phosphoinositides (reviewed in [4]). Chemokines (chemotactic cytokines)
are small heparin-binding proteins that are known to play a crucial role in directing the movement
of cells throughout the body [5]. Most chemokines bind several receptors and a single receptor can
often bind several chemokines, forming an intertwined web in which a sole role can be played by
several elements.
Chemokines and chemokine receptors are essential in dendritic cell (DC) maturation and (B and T)
cells’ development [6,7]. Indeed, recent studies indicated that chemokines have a role in the chemotaxis
of particular T cell or monocyte subsets that had not been identified previously [8,9]. The chemokine
family can be either pro-inflammatory or homeostatic. The former is released due to a pathogen; an
infection or other pro-inflammatory stimuli that causes the induction of chemokines that will direct the
recruitment of leukocytes towards the site of injury [10]. Depending on the type of inflammation, a
different immune cell subset will be recruited to the site [11], whilst the latter is constitutively expressed
in specific tissues and has roles in tissue development (such as angiogenesis or neovascularization) or
basal leukocyte migration.
A considerable body of evidence highlights the importance of chemokines and their receptors
during tumor progression and metastasis. Initially, chemokines selectively regulate the recruitment and
trafficking of leukocyte subsets during homeostasis and inflammation [12,13]. However, it is becoming
increasingly clear that they are also responsible for controlling the function of several tumor-promoting
processes including host immune responses against malignant cells, cancer cell growth, angiogenesis
and metastasis [14,15]. Chemokine receptors are further involved in the regulation of cancer progression
through the recruitment of immune cell subsets. Importantly, there is a paucity of information from
in vivo experimental systems regarding the specific function of individual chemokine receptors in
cancer progression, whereas only very little data exist regarding their role in primary tumor formation.
The discovery that cancer cells overexpress C-C Chemokine receptor 7 (CCR7), which directs
them to organs that express their ligands CCL21 and CCL19, led to an increase in reports confirming
that chemokine receptors were present in a non-random manner in many other cancers. A positive
correlation between chemokine receptor expression and worse prognosis has been found in most
but not all cancers. In breast cancer, it has been proved that the chemokine receptors CXCR4, CCR7,
CCR6 and CXCR3 and their ligands have been associated with metastasis [16,17]. Despite all the
evidence linking CCR7 expression to a poorer prognosis, still much remains unknown about the exact
mechanisms behind its upregulation and its role in breast cancer progression, which will be discussed
in details in this review.
2. Chemokine Receptors in Cancer
The recruitment of immune cells to the tumor site is mediated by the actions of chemokines and
their specific ligands, which have also been widely linked to cancer progression and metastasis. Upon
the binding of the chemokine ligands, the receptor undergoes a conformational change. This results in
the expression of several genes and activates a signaling cascade that, depending on the context, can
stimulate cellular growth, migration, pseudopodia formation, adhesion, as well as angiostasis [18].
It was thought that metastasis was regulated through factors such as the size of the vessels or the
difference in pressure between the blood and the organs [19]. However, because of the involvement of
chemokine receptors in the migration of cells, they have been widely implicated in the metastasis of
cancer cells throughout the body [10]. Tumor cells, through the expression of lymphoid chemokine
receptors, may exploit the physiological lymphatic trafficking system to mediate invasion into the
lymphatic vasculature [20]. Chemokine receptors can potentially facilitate tumor dissemination at
numerous stages of the metastatic cascade, including vascular extravasation, protection from the host,
adherence of tumor cells to endothelium, proliferation, colonization and angiogenesis [20,21]. To
date, the most recognized receptor/ligand pairs in these phenomena include CXCR4/CXCL12 and
CCR7/CCL21.
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3. C-C Chemokine Receptor 7 (CCR7) in Cancer
C-C Chemokine receptor 7 (CCR7), is a GPCR commonly expressed by T-cell subset central
memory cells, thymic T-cells, B cells, mature DCs and other rare cell subsets such as CD4+ CD25+
splenocytes [22–25].
CCL21 and CCL19 are constitutively expressed at the beginning of the lymphatic vessels and
in lymphoid organs. They are present on several stromal cells and on the high endothelial venules
(HEVs). Unlike CCL19, CCL21 binds to glycosaminoglycans (GAGs) and immobilizes on the surface
of endothelial cells [26]. This means that only CCL21 is required for the intravasation into different
lymphatic vessels [27]. Interestingly, the literature showed that the stimulation of CCR7 with both CCL19
and CCL21 ligands induces G-protein activation, ERK 1/2 signaling pathway, calcium mobilization
and cell migration [28]. CCR7 desensitization and its ERK activation are mediated through β-arrestin,
which may explain why the phosphorylation is four times stronger with CCL21, implying that CCL19
effects may be more transient than with CCL21 [29]. Internalized CCR7 is recycled back to transfected
cell lines or the plasma membrane of primary T cells to participate in cell migration, whereas CCL19 is
sorted to lysosomes for degradation [30].
While the overexpression of CXCR4/CXCL12 is correlated with the homing of cancer cells to the
liver, lung, bone marrow and lymph nodes, the overexpression of the CCR7/CCL21 axis has mainly
been related to lymph node metastasis [18]. It also plays a critical role in the progression of many
different malignancies such as breast [31], gastric [32], skin (melanoma) [33], head and neck [34],
lung [35], esophageal [36], hepatocellular [37], cervical [38], thyroid [39], tonsillar [40], colorectal [41]
and prostate cancers [42] as summarized in (Table 1). In the majority of these cancers, larger tumor size
and deeper invasion was associated with CCR7 expression [43]. Taken together, the CCR7-mediated
cell migration underlies a broad range of immune system activities and therefore it is important to
understand its mechanism.
Table 1. The roles of C-C Chemokine receptor 7 (CCR7)/CCL21 in various human cancers.
Tumor Type Observations References
Breast Cancer Correlates and promotes lymphogenesis and metastasis.CCL21 induces actin polymerization and migration. [18,44–46]
Human Bladder Cancer Enhances the migration, invasion and tumorproliferation/ correlates with poor prognosis. [43,47]
Cervical Cancer Metastasis and poor prognosis. [38,40]
Colorectal Cancer Poor prognosis and metastasis. [48–50]
Gastric Cancer Overall poor survival as well as metastasis and EMT. [51,52]
Head and Neck Cell Carcinoma CCR7/CCL21 correlates with metastasis. [53,54]
Lung Cancer Tumor dissemination and metastasis. [55,56]
Lymphomas Poor prognosis and tumor dissemination. [57,58]
Melanomas Metastasis and poor outcome. [18,59]
Esophageal Cancer
Expression of CCR7 correlates with poor prognosis and
metastasis. CCL21 induces pseudopodia formation, cell
metastasis and angiogenesis.
[60–62]
Prostate Cancer Tumor growth, metastasis and poor survival throughlymphatic metastasis. [63,64]
3.1. Mode of Action of C-C Chemokine Receptor 7 (CCR7) in Migration and Adhesion
Cellular migration in vivo and in vitro is dependent on both the physical and biochemical
properties of cells and the extracellular matrix (ECM) [65]. For cells to extravasate from the bloodstream
and adhere to the endothelium, chemokines need to be bound to the GAGs present in the ECM [66].
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This is an electrostatic interaction where the chemokine C-terminal region is positively charged due
to the presence of basic amino acids such as lysine and arginine, whilst GAGs are highly negatively
charged due to the presence of carboxylate and sulphate residues [66]. Recent work has shown that
cells can sense the mechanical stiffness of their physical environment, and environmental stiffness can
lead to changes in cellular gene expression and phenotype [67]. Moreover, chemokines can induce
migration towards an increasing concentration of a chemoattractant or migration towards a decreasing
concentration of a chemorepellent creating a concentration gradient called haptotaxis [68]. In mature
DCs, for instance, immobilized CCL21 causes haptotaxis and integrin activation, while soluble CCL21
or CCL19 induce chemotaxis, and both can occur in combination [69].
The homing and migration of lymphocytes as well as CCR7-positive malignant cells metastasis
into secondary lymphoid tissue (SLT) are precisely regulated by complex chemokine–chemokine
receptor interaction in the microenvironment. CCR7-mediated T cell migration within SLT is critical
for T cell activation and differentiation in adaptive immunity. Investigating the migratory response of
CCR7 expressing T cells within a certain chemokine environment will lead to a better understanding
of the mechanism of directional migration of T lymphocytes [70]. An investigation of CCR7 function in
chemotaxing cells may also help to understand its role in cancer metastasis [71].
CCR7 is of particular interest in understanding metastasis because CD4+ T cells and DCs require
CCR7 expression to migrate through lymphatic vessels [72]. The lymphatic vessels function as the sink
for the interstitial flow; it has been postulated that interstitial flow and CCL21 act in conjunction to
guide migrating tumor cells to lymphatics in the formation of metastases [73].
Pre-clinical studies have demonstrated that CCL19/CCL21 producing lymphatic endothelial cells
can actively guide the chemotactic migration of CCR7-expressing tumor cells [33]. Additionally,
CCL21 has been shown to promote the generation of new lymphoid-like structures within the tumor
microenvironment, which are characterized by the infiltration of immune-suppressive T-regulatory
cells and myeloid-derived suppressor cells [74]. However, the role of CCL21 during tumor progression
remains somewhat controversial, with tumor-suppressive properties also been reported. CCL21 is
a potent chemoattractant for tumor-infiltrating lymphocytes, which can exert a robust anti-tumor
immune response especially during the early stages of tumor progression [75]. A recent clinical study
reported an improved outcome associated with the increased infiltration of CCR7-positive T-cells
within advanced colorectal carcinoma [76]. Within gastric cancers, CCR7 expression in the primary
tumor was reported as the most important factor in determining lymph node metastasis. There is also
preclinical evidence that CCR7 expression is a rate-limiting step for mediating the lymphatic spread of
pancreatic ductal adenocarcinoma [77].
3.2. C-C Chemokine Receptor 7 (CCR7) and Angiogenesis
CCR7 has also been linked to the creation of new blood and lymphatic vessels in breast cancer
patient samples, though the mechanism is still not well understood [44]. This lymphangiogenesis is
mediated through VEGF-C and its receptor VEGFR-3 [44]. Indeed, the overexpression of this growth
factor has been well documented to increase lymph node metastasis [78]. Interestingly, there are also
studies suggesting that whenever tumor cells express CCL21 it has an anti-tumorigenic effect through
the inhibition of angiogenesis and increase of leukocyte recruitment, in particular of CD8 + T-cells and
DCs [79]. However, this immune response is suboptimal (as stated previously) and this could be due
to the lack of maturation of the DCs.
4. C-C Chemokine Receptor 7 (CCR7) and Breast Cancer
The receptor CXCR4 is the most studied of all chemokine receptors in cancers. Its roles in
breast cancer, including cell survival, proliferation, motility, invasion, angiogenesis, recruitment and
activation of a number of different cell types, as well as metastasis are well documented [80]. CCR7
is often up-regulated together with CXCR4 in cancer [81]. In addition, these two receptors form a
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heterodimer on metastatic breast cancer cells, which activates alternative signaling pathways and
promotes a metastatic phenotype [82].
In breast cancer, hypoxia has been shown to increase CCR7 expression through the
hypoxia-inducible factor 1 (HIF-1)-mediated activation of the endothelin receptor A [83]. Epigenetic
factors could also play a role in CCR7 upregulation, with histone deacetylation and DNA methylation
playing a role in gene activation [84]. Despite all the evidence linking CCR7 expression to a poorer
prognosis, still much remains unknown about the mechanisms behind its upregulation.
The interaction between CCR7 and CCL21 has been shown to improve the immunogenicity
of CCR7-expressing breast cancer cells [85]. It also induces actin polymerization and pseudopodia
formation, resulting in increased cell motility as illustrated in (Figure 1) [86].
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Figure 1. General C-C Chemokine receptor 7 (CCR7) chemokine dual role in the immune system and
breast tumor metastasis. (A) CCR7 role in the adaptive immune system; CCL19/CCL21 chemokine
expression activates CCR7 to promote dendritic cells (DC) and T-cell maturation. CCL21 and CCL19
chemokines determine differential signaling. Both chemokines CCL21 and CCL19 have the ability
to display G-protein signaling cascades, however only CCL19 can trigger the β-arrestin recruitment.
(B) Chemokine receptors in the metastatic process. (As illustrated) CCR7 chemokine receptor activation
may play key roles in several steps during the process of metastasis; arrest; dissemination; invasion,
extravasation; survival/proliferation) all under the control of the immune system trafficking to the site
of inflammation.
4.1. Molecular Aspects of C-C Chemokine Receptor 7 (CCR7) Signaling Cascades in Breast Cancer
Chemokine signaling in which a cell responds to a self-secreted chemokine is known as autocrine
signaling, as opposed to paracrine signaling in which a cell responds to a chemokine secreted by a
neighboring cell [87]. Both autocrine and paracrine signaling are well established mechanisms that
drive tumor cell phenotype and migration.
There are a large number of chemokines that regulate the downstream effector molecules which
may account for the various effects of these recipients in tumor pathology. To date, the effector
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molecules and unique mechanisms controlling cell chemotaxis, proliferation, survival and motility
have been highly considered in chemokine receptor signaling in cancer [88,89].
Measuring chemokine ligands’ ability to induce early physiological changes, chemotaxis, actin
polymerization and calcium mobilization is routinely performed in vitro to assess chemokine receptor
functionality [90]. These findings provide evidence that CCR7 activation is cell-dependent via
distinct mechanisms of actions. A number of key metastasis steps have been shown to facilitate
tumor dissemination, including the endothelium adhesion of tumor cells, blood vessel extravasation,
protection from host responses, angiogenesis, proliferation and metastatic colonization [91].
It is thought that chemokine responses are activated through key survival pathways such as the
PI-3K and AKT, JAK/STAT, ERK 1/2, JNK, GSK-3α/β and MAP kinase [73,92,93]. Moreover, the exact
signaling mediators in primary and invasive tumors are yet to be elucidated, although chemokine
signals have been characterized in leukocytes with few currently available evidences on other cell
types. The CCL21 binding to CCR7 has been reported to stimulate the activation phosphorylation
of AKT (PI-3K pathway) that mediates a wide variety of intracellular targets to induce cell survival
and inhibit apoptosis in many different types of cancer cells [94,95], as well as an implied effect on
cell proliferation and motility [96]. This was further confirmed by the ability of CCR7 ligands to
induce early migratory responses such as cytoskeleton remodeling and chemotaxis in metastatic breast
cancer cells [97]. CCR5 and CCR7 enhance protooncogene c-Fos expression by JAK/STAT pathway
in leukemia cells [98]. The activation of ERK in lymphoma and non-small lung cancer cells is also
implicated in CCR3, CCR7 and CCR8 by inducing phosphorylation, proapoptotic protein inactivation
and the activation of survival mechanisms [47,99].
Chemotactic responses and actin polymerization are not induced following CCR7 ligand-binding
activation in non-metastatic breast cancer cells. Chemokine signaling pathways are mediated by the
mobilization of the calcium flux through the activation of GPCRs, specifically the Gαi subunit that
results from the inhibiting of adenylyl cyclase-mediated cAMP [100,101]. The pre-treatment with the
Gαi inhibitor “pertussis toxin” impairs this calcium induction responsiveness. In addition, Adenylyl
cyclase-mediated cAMP, stimulated by forskolin, is inhibited by CCL19 ligand treatment only in
invasive breast cancer cells [102]. Therefore, functional Gαi signaling after chemokine treatment was
only observed in the metastatic breast cancer cells. However, even after the addition of a phosphatidic
acid, non-chemokine GPCR and non-metastatic cells did not respond. This might have been caused by
the disruption of the upstream signaling events.
Hematopoietic and non-hematopoietic tumors metastatic to lymph nodes are correlated with
tumor-dependent CCR7 expression. Physiologically, this indicates mature DCs and naive T lymphocytes
recruitment to lymph nodes [73,103]. However, the induced expression of CCR7 in breast cancer cells
switches metastasis from the lung to lymph nodes, indicating that the organ specificities of metastatic
cancer cells might be sufficient by a single chemical receptor [31]. In some experimental settings,
epithelial-to-mesenchymal transition (EMT) was triggered by a PI3K-mediated activation of snail
and glycogen synthase kinase (GSk)-3β in hepatocellular carcinoma cells through CCL21/CCR7 and
CXCL5/CXCR2 binding [104]. Moreover, TGF-β is reported to stimulate EMT through crosstalk with
NF-κB signaling pathway in gastric cancer cells [51].
The pathways used by CCR7 to facilitate metastasis are not fully understood. It has been reported
that CCR7 facilitates cancer progression by manipulating cancer cells’ anoikis and mobility [82] as well
as controlling the tumor microenvironment, including the inflammatory responses, immune tolerance
and T cell activation [105,106]. Downstream potential signaling mediators of CCR7 have been reported
to be associated with metastasis, such as ALDH3A2, AnXA6, EpCAM, and PVR [107]. MMPs play an
important role in tumor cell invasion and migration. It has been illustrated that CCR7 triggers AKT
which eventually leads to the secretion of MMP-2/9. The silencing of CCR7 thus acts as a targeted
therapy to inhibit AKT and MMPs expression and attenuates MCF-7 cell proliferation, invasion and
EMT [45]. A schematic illustration of CCR7 binding to the cognate ligands CCL19/CCL21 to induce
several signaling transduction pathways in breast cancer is shown in (Figure 2).
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Figure 2. CCR7 chemokine receptor binding to the cognate ligands CCL19/CCL21 inducing signaling
transduction pathways in breast cancer. Schematic representation of the seven transmembrane
G-protein coupled receptor (CCR7) activation and internalization by ligand binding which triggers
several signaling pathways cascades as follows: a. The binding of chemokine ligands CCL19/CCL21 to
their CCR7 GPCRs leads to the activation of a G-α subunit and a Gi-βγ heterodimer. b. This initiates
downstream signaling effectors that further lead to signaling cascades, such as the activation of ERK1/2,
PI3K/AKT, Rho GTPases, MAPK, and JAK/STAT, which can promote the transcription and expression
of different genes such as MMPs. c. All the above induce broad biological effects including chemotaxis,
cell survival/proliferation, matrix degradation, reorganization of the actin cytoskeleton, adhesion,
cell migration, invasion and angiogenesis. GPCR, G-protein-coupled receptors; ERK, extracellular
signal-regulated kinase; JNK: c-Jun N-terminal kinase; PI3K, Phosphatidyl inositide-3-kinase; AKT,
protein kinase B; NF-κB, nuclear factor-κB; Rho, Ras homolog gene family; PLC, phospholipase C;
MAPK, mitogen-activated proteins kinase; JAK, Janus-activated kinase; TFs: Transcription factors,
MMP, matrix metalloproteinase.
CCR7 expression is regulated by transcription factors, epigenetic and miRNAs mechanisms.
Transcription factors such as SP-1, AP-1, NF-κB and NF-AT1 can bind and regulate CCR7’
expression [108,109]. Nevertheless, it has not been well described whether these factors are correlated
with tumor metastasis. The constituent expression of Ets-1, an oncogene that is involved in EMT, is
well associated with the expression of CCR7 and cell migration activity in MDA-MB-231 [110,111].
Studies in the field of breast cancer have shown that the correlation between the expression of CCR7
and clinical pathogenicity in human breast cancer is important, including vascular invasion, lymph
node metastasis and tumor grade [112]. However, other reports found contradictory results [113].
Hence, to gain greater certainty, more studies are recommended to determine the association between
patient survival, recurrence risk and metastasis with the expression of CCR7. Moreover, CCR7
expression may enhance breast cancer cells’ migration to lymph nodes. Nevertheless, it is still not
fully understood how this migration has contributed to a better prognosis. One explanation could
be that positive CCR7 cancer cells primarily target metastasis to lymph nodes as well as empower
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the immune system to eliminate escaped cancerous cells [114]. Remarkably, Gracio et al. reported
that the alternative splicing of CCR7 has been correlated to clinical results [115]. Therefore, the
interactions between this essential post-transcriptional regulation and patient survival should be
carefully investigated in correlation with CCR7 alternative splicing in breast cancer [116]. Nevertheless,
this issue should be addressed in future studies to reveal the impact of CCR7 expression.
4.2. The Expression and Functional Role of C-C Chemokine Receptor 7 (CCR7) in Breast Cancer Cells In Vitro
The up-regulation of specific chemokine/receptor pairs has been reported in many human cancers
including lung, breast, colon, prostate, gastric and melanoma [91,117], although at this point their
precise mechanisms of action at each recurring event of metastasis are still being investigated. Recently,
the expression of CXCR4 and CCR7 have received considerable attention in tumor cells for their direct
involvement in metastasis. A variety of cancer cell lines and primary tumors tissues reported an
expression of these chemical receptors and the interaction with the associated ligands to promote
the in vitro and in vivo movement of cancer cells [38].
The CCR7 expression was evaluated in breast cancer cells in vitro to ascertain whether the rates
of expression of a chemokine receptor contribute to the pathogenicity of breast cancer. A group of
cell lines was used; each was originally derived from patients with different types of metastatic breast
disease displaying various degrees of invasiveness. The examination of the CCR7 expression revealed
significant levels of expression in different breast cell lines. Studies reported low CCR7 mRNA levels
in MCF-7, MDA-MB-231 and T47D [18,118], no expression at mRNA levels in MDA-MB-231 [119], and
inducible levels in MCF-7, MDA-MB-231, and SKBR3 [83]. Clinical studies revealed that breast cancer
tumors show cytoplasmic CCR7 expression [120,121]. The same cytoplasmic-confined phenomena
were also reported later in 4T1 cells [122]. These data confirm the internalization and activation
of the CCR7 receptor upon ligand binding. It is also worth mentioning that CCR7 expression was
detected with similar levels in both immortalized normal breast epithelial cells (MCF10A) as well as in
a highly invasive breast cancer cell line (MDA-MB-231) [106]. These data strongly suggest that CCR7
expressions are not strictly limited to invasive cells and would not be a useful predictor of metastasis
in aggressive breast cancer. Although the CCR7 physiological function is known in normal breast
epithelial cells, their exact role remains unknown but valuable to be determined in non-metastatic
breast cancer cells. Moreover, it can be predicted that cells gain selective advantages to proliferate,
colonize, survive and migrate at secondary sites when chemokine receptors are activated through
cancer progression.
4.3. The Role of C-C Chemokine Receptor 7 (CCR7) on Breast Cancer Metastasis In Vivo
Metastasis is one of the problematic tumor processes to study in vitro since the tumor progression
relies on sequential events that are dependent on the characteristics of the tumor cells and their
interactions with the tissue environment [123]. Therefore, more relevant studies of metastasis are
thought to originate from those performed in vivo. Significantly, mice models of different human
cancers have become a central part of many types of biomedical research as they provide the most
experimentally accessible mammalian model that shares genes, physiology and organ structure with
the human system [124].
To provide further insight into chemokine-mediated metastatic mechanisms, the expression
of CCR7 on mammary epithelial cell lines was modulated using an shRNA system based on the
ability to deliver and stably express shRNAs, to study the effect of chemokine modulation on the
metastatic propensity of breast cancer cells in vivo [125]. The silencing of CCR7 decreased the in vitro
proliferation, migration and invasion of CCL21/CCL19-induced MCF-7 and MDA-MB-231 breast cancer
cells [45,126]. Furthermore, the depletion of CCR7 in BALB/c mice inhibited orthotopically injected 4T1
cells metastasis, while tail veins’ injection had no impact on breast cancer metastasis. These outcomes
were consistent with the previous findings, showing that CCR7 did not affect liver and lung metastasis
when pancreatic cancer cells (TD-2) were injected via tail veins, but rather increased B16 cell metastasis
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to lymph nodes [127]. On the other hand, CCR7 overexpression in MMTV-PyMT-mediated breast
cancer cells, injected orthotopically into FVB mice, significantly increased lymph node metastasis [31].
CCR7 expression has been reported in particular to increase B16 metastatic capacity via the
lymphatic system but not through a blood-borne pathway [128]. At first, CCR7 had a significant role as
stimulated DCs migrated through various lymph vessels to specific lymph nodes. Subsequently, it was
suggested that neoplastic cells also enter lymph vessels to improve lymphatic dissemination, shown
for B16 melanoma cells [129]. The formation of the CCR7 metastatic lymph node expressing B16 cells
was effectively blocked by the neutralization of anti-CCL21 [129], which confirmed the role of CCR7
during metastasis. Given the contrasting studies, the exact relationship between the expression of
chemokine in metastatic tumor progression and their potential role still requires considerable attention.
Higher levels of CCR7 mRNA was detected in cancer tissue compared to the normal counterpart
lung tissues, suggesting that CCR7 expression could be used to predict the metastasis of the lymph
node before surgery as a diagnostic tool to improve the overall treatment plan for non-small cell lung
cancer (NSCLC) [55]. Moreover, the CCR7 presence was directly related to the lymph node metastases
development in NSCLC [35]. In addition, the expression of chemokine receptors in clinical samples may
help correlate their levels with the outcome of cancer patients. Interestingly, based on the expression
status of hormonal receptors, triple-negative breast cancer (TNBC) is associated with poor prognosis,
higher metastasis and worse outcomes than other subtypes due to the absence of efficient targeted
therapies [130]. In breast cancer tissues, CCR7 has been highly expressed especially in the luminal
B-type and TNBC compared to the luminal A type [114,131]. Therefore, tumor microenvironment
signals are likely to be interpreted differently in luminal-B cells than those in luminal-A cells. Thus, the
tumor microenvironment factors do not inhibit the responsiveness of luminal-B cells to chemotactic
cues mediated through the CCR7/CCL21 axis [46].
Several experimental approaches using specific chemokine antagonists, neutralizing antibodies,
knockout mice and targeted gene disruptions have been reported to be useful tools for discerning the
role of chemokines and their receptors in vivo [132,133]. Therefore, these methods may potentially
provide a basis for the development of future therapeutic agents. Studies involving the inhibition of
CCR7 expression on cancer cells are yet to be explored at both the in vitro and in vivo level.
5. Therapy and Future Directions
For most chemokine receptors, removing their cytoplasmic tail impairs endocytosis [134,135]. For
CCR7, the deletion of the entire cytoplasmic tail did not totally block the receptor endocytosis and
recycling but also eliminated the CCL19/CCL21-induced chemotaxis. Indeed, in vivo CCR7 C-terminal
partial truncation decreases the receptor internalization, while maintaining the chemotaxis ability to
CCR7 ligands [135], and prevents lymphocyte adhesion and extravasation to the HEVs [136]. Additional
studies reported that the intra-tumoral injection of recombinant CCL21 significantly delayed tumor
progression and stimulated cytotoxic immune responses [85,137]. Moreover, in vitro experiments have
demonstrated that blocking the CCR7 receptor decreases the incidence of metastasis [86,121].
Initial reports suggested that CCL21 and CCL19 were anti-tumorigenic, as they could attract
lymphocytes that would attack the tumor [79]. However, it has been described that in CCL21-expressing
tumors, the chemokines create a tolerogenic environment where the lymphocytes behave similarly
to the lymph node stroma [74]. Preliminary studies into the use of CSC vaccines by pulsing DCs
with CSC lysates (based on the expression of aldehyde dehydrogenase) to generate B cell-mediated
immunity against CSCs in mouse models of melanoma and squamous cell carcinoma have been
conducted. The application of the DC vaccine reduced the development of primary tumors and
metastasis and interestingly, this was associated with a significant decrease in the expression of CCR7
and its ligand CCL21 [138]. Therefore, the inhibition of CCR7 may potentially be used in combination
with conventional chemotherapeutics in a multipronged approach to eliminate both rapidly dividing
bulk tumor cells and quiescent stem-like cells.
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The function of CCR7/CCL21 in cancer appears to be controversial; it may play a pro- or anti-tumor
function depending on where it is expressed. In tumor cells, it induces development and progression,
whereas when expressed by immune cells such as dendritic or T cells, anti-tumor responses are
detected [91]. Moreover, the response of the host to recognize poorly immunogenic tumors is one of
the challenges in developing cancer immunotherapy. DCs are bone-marrow-generated leukocytes
with high levels of MHC expression and co-stimulatory molecules [139]. Their ability to consume,
process and present antigens, combined with their ability to activate and expand antigen-specific T
cells, make them a promising target for the development of cancer immunotherapy strategies [140].
Recent studies in cancer immunotherapy have investigated the use of WT CCL21 as a chemoattractant
of dendritic and T cells to the tumor [141]. For example, the FDA has approved immunotherapy using
DCs against metastatic, asymptomatic prostate cancer [142]. The vaccine was considered safe and
showed an encouraging response to the tumor although these trials are still underway [143,144]. A
more advanced delivery system using immunocompetent mice was used to evaluate this either by
encoding CCL21 in an adeno-recombinant associated virus to enable its transduction following the
intra-tumoral implant [145], or only by directly injecting CCL21 into the tumor cells, both resulting in
reduced tumor development [146]. Another alternative is to inject exaggerated CCL21-transduced
DCs or fibroblasts that mediate the functional differentiation and recruitment of innate and adaptive
immune cells into the tumor, which has been shown to destroy cancer cells [147]. In summary, the dual
roles of the CCR7/CCL21 axis in protective immunity and tumor promotion suggest that their targeted
therapies must be carefully evaluated.
This comprehensive review provided an insight into chemokine-mediated mechanisms performed
in breast cancer cells both in vitro and in vivo, specifically CCR7; there are still important questions
that remain to be answered. It will be valuable to gain a broader understanding of the functional role
of chemokines and their receptors in different cancers other than breast cancer. In addition, given
the complex process of metastasis, it is likely that chemokine receptors may function at several steps
and therefore, the use of specific in vivo models may assist in elucidating the precise stage at which
chemokines and their receptors influence the metastatic pathway. Finally, it would be recommended
to examine the effect of chemokine receptor expression on the growth of primary tumors using an
orthotopic cancer model to verify the precise role of chemokines during metastasis. The understanding
of chemokine-mediated pathways and consequently, their potential disruption may provide useful
information for the design of new strategies to treat breast cancer.
6. Conclusions
In recent decades, there have been vast advances in our knowledge regarding the roles of the
chemokines in cancer progression. In addition, most chemokines have been reported to act as promoting
factors for tumor growth and proliferation, angiogenesis and metastasis. This could be due to the
promiscuity of chemokine and chemokine receptor interactions in cancer cells.
Participation in cancer cell invasion, metastases and tumor development was reported with the
CC Chemokine receptor 7 (CCR7). CCR7 and its receptors have been particularly reported to stimulate
the tumorigenesis of breast cancer. It also played a novel role in inducing lymphangiogenesis in the
experimental model of breast cancer. It was also accompanied with EMT in human breast carcinoma.
Furthermore, CCR7 has been involved in the metastasis of the lymph nodes, invasion, migration
and EMT. Findings showed that the EMT progression in breast cancer cells was controlled by the
CCL19/CCR7 axis and facilitated the invasion and migration process of tumor cells by triggering
several signaling pathways. On the basis of this review, CCR7 has a critical role in breast cancer
progression. Thus, it might be elucidating that CCR7 could be a novel target for tumor therapy when
used in combination with chemotherapy or immune checkpoint therapy. For verification of CCR7 and
its ligands as a therapeutic target for breast cancer progression, further studies are required to illustrate
their function and the mechanism of their actions involved in breast cancer progression.
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